M
Meg Jardine
Researcher at University of Sydney
Publications - 230
Citations - 13515
Meg Jardine is an academic researcher from University of Sydney. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 44, co-authored 188 publications receiving 9207 citations. Previous affiliations of Meg Jardine include The George Institute for Global Health & University of Queensland.
Papers
More filters
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
Toshiharu Ninomiya,Vlado Perkovic,Bastiaan E. de Galan,Bastiaan E. de Galan,Sophia Zoungas,Avinesh Pillai,Meg Jardine,Anushka Patel,Alan Cass,Bruce Neal,Neil R Poulter,Carl-Eric Mogensen,Mark E. Cooper,Michel Marre,Bryan Williams,Pavel Hamet,Giuseppe Mancia,Mark Woodward,Mark Woodward,Stephen MacMahon,John Chalmers +20 more
TL;DR: In this article, the effects of albuminuria and reduced estimated GFR (eGFR) on the risk for cardiovascular and renal events among individuals with type 2 diabetes were investigated. But, there was no evidence of an interaction between the effect of higher eGFR and lower UACR.
Journal ArticleDOI
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin,Marcello Tonelli,Joseph V. Bonventre,Josef Coresh,Jo Ann Donner,Agnes B. Fogo,Caroline S. Fox,Ron T. Gansevoort,Hiddo J.L. Heerspink,Meg Jardine,Bertram L. Kasiske,Anna Köttgen,Matthias Kretzler,Andrew S. Levey,Valerie A. Luyckx,Ravindra L. Mehta,Orson W. Moe,Gregorio T. Obrador,Neesh Pannu,Chirag R. Parikh,Vlado Perkovic,Carol A. Pollock,Peter Stenvinkel,Katherine R. Tuttle,David C. Wheeler,Kai-Uwe Eckardt +25 more
TL;DR: An action plan and performance framework based on ten themes to strengthen CKD surveillance, tackle major risk factors for CKD, and enhance understanding of the genetic causes of CKD is presented.
Journal ArticleDOI
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendon L. Neuen,Tamara Young,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink,Bruce Neal,Bruce Neal,Bruce Neal,Vlado Perkovic,Laurent Billot,Kenneth W. Mahaffey,David M. Charytan,David C. Wheeler,Clare Arnott,Clare Arnott,Clare Arnott,Severine Bompoint,Adeera Levin,Meg Jardine +17 more
TL;DR: Evidence is provided that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function and there was clear, separate evidence of benefit for all eG FR subgroups, including for participants with a baseline eGFR 30-45 mL/min per 1·73 m2.
Journal ArticleDOI
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
Hiddo J.L. Heerspink,Hiddo J.L. Heerspink,Toshiharu Ninomiya,Sophia Zoungas,Sophia Zoungas,Dick de Zeeuw,Diederick E. Grobbee,Diederick E. Grobbee,Meg Jardine,Martin Gallagher,Matthew A Roberts,Alan Cass,Bruce Neal,Vlado Perkovic +13 more
TL;DR: Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population.